Literature DB >> 1646320

Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain.

D Lacroix1, P Blier, O Curet, C de Montigny.   

Abstract

The present studies were undertaken to assess in vivo the effects of repeated administration of the norepinephrine (NE) reuptake blocker desipramine (DMI) (5 or 10 mg/kg/day x 14 days) on five subsets of adrenoceptors and on the effectiveness of the NE reuptake process in the rat central nervous system. These receptors were: 1) the postsynaptic alpha-2 adrenoceptors which signal the suppressant effect of microiontophoretically applied NE on the firing activity of dorsal hippocampus pyramidal neurons; 2) the postsynaptic alpha-1 adrenoceptors which mediate the short-latency suppressant effect of endogenous NE, released by the electrical stimulation of the locus ceruleus (LC), on the firing activity of these same neurons; 3) the postsynaptic beta adrenoceptors which mediate the long-latency excitatory effect of LC stimulation on hippocampus pyramidal neurons; 4) the alpha-2 autoreceptors located on NE terminals in the hippocampus; and 5) the alpha-2 autoreceptors located on the cell body of LC NE neurons. The suppressant effect of microiontophoretic applications of NE on dorsal hippocampus pyramidal neurons was not changed by the long-term DMI treatments. The recovery time of the firing activity of these neurons after microiontophoretic application of NE, an index of the activity of the NE reuptake process, was the same in control and DMI-treated rats. However, the prolongation of this recovery time by the acute i.v. administration of DMI reached a plateau at a lower cumulative dose in long-term DMI-treated than in control rats. These results thus suggest that long-term administration of DMI did not affect the function of the NE transporter but reduced the number of DMI binding sites. The effectiveness of the 1 Hz stimulation of the LC in suppressing of the firing activity of pyramidal neurons was unchanged by either long-term DMI treatment (5 or 10 mg/kg/day), whereas that of the 5 Hz stimulation was enhanced only in rats on the 10-mg/kg regimen. This suggests that the function of terminal alpha-2 autoreceptors was decreased after this latter DMI regimen, because the reduction of the efficacy of the stimulation obtained by increasing the frequency from 1 to 5 Hz has been shown to be due to the activation of terminal alpha-2 adrenergic autoreceptors. In keeping with this interpretation, the reduction of the effectiveness of the stimulation of the LC by the systemic administration of the alpha-2 adrenoceptor agonist clonidine was attenuated in rats treated with the 10-mg/kg/day regimen of DMI, but not in those with the 5-mg/kg/day regimen.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex.

Authors:  R W Invernizzi; S Parini; G Sacchetti; C Fracasso; S Caccia; K Annoni; R Samanin
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

3.  Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion.

Authors:  Ramez Ghanbari; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2011-03-29       Impact factor: 4.530

4.  Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain.

Authors:  G Sacchetti; M Bernini; A Bianchetti; S Parini; R W Invernizzi; R Samanin
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study.

Authors:  Y Mateo; B Fernández-Pastor; J J Meana
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

Authors:  Pamela J McMillan; Sylvia S White; Allyn Franklin; J Lynne Greenup; James B Leverenz; Murray A Raskind; Patricia Szot
Journal:  Brain Res       Date:  2010-12-11       Impact factor: 3.252

Review 7.  Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.

Authors:  Claire Rampon; Bruno P Guiard; Basile Coutens; Antoine Yrondi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-10       Impact factor: 4.415

8.  Effect of desipramine-induced blockade of neuronal uptake mechanisms on adrenoceptor-mediated responses in the guinea-pig colon.

Authors:  F Marino; M Marcoli; F De Ponti; M Cosentino; S Lecchini; G M Frigo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

9.  The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin.

Authors:  J A Ruiz-Ortega; L Ugedo; J Pineda; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

10.  Chronic cold exposure increases RGS7 expression and decreases alpha(2)-autoreceptor-mediated inhibition of noradrenergic locus coeruleus neurons.

Authors:  Hank P Jedema; Stephen J Gold; Guillermo Gonzalez-Burgos; Alan F Sved; Ben J Tobe; Theodore Wensel; Anthony A Grace
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.